Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
56
AMPH Quote, Financials, Valuation and Earnings
Last price:
$27.12
Seasonality move
:
2.09%
Day range:
$26.97 - $27.84
52-week range:
$20.39 - $45.39
Dividend yield:
0%
P/E ratio:
12.04x
P/S ratio:
1.85x
P/B ratio:
1.61x
Volume:
405K
Avg. volume:
433.4K
1-year change:
-38.71%
Market cap:
$1.2B
Revenue:
$732M
EPS (TTM):
$2.26
Analysts' Opinion
-
Consensus RatingAmphastar Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.33, Amphastar Pharmaceuticals, Inc. has an estimated upside of 17.86% from its current price of $27.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $27.15.
Fair Value
-
According to the consensus of 5 analysts, Amphastar Pharmaceuticals, Inc. has 17.86% upside to fair value with a price target of $32.33 per share.
AMPH vs. S&P 500
-
Over the past 5 trading days, Amphastar Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Amphastar Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amphastar Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Amphastar Pharmaceuticals, Inc. reported revenues of $191.8M.
Earnings Growth
-
Amphastar Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Amphastar Pharmaceuticals, Inc. reported earnings per share of $0.36.
Enterprise value:
1.6B
EV / Invested capital:
1.13x
Price / LTM sales:
1.85x
EV / EBIT:
10.84x
EV / Revenue:
2.25x
PEG ratio (5yr expected):
0.43x
EV / Free cash flow:
14.65x
Price / Operating cash flow:
12.05x
Enterprise value / EBITDA:
7.68x
Gross Profit (TTM):
$343M
Return On Assets:
6.91%
Net Income Margin (TTM):
15.43%
Return On Equity:
14.9%
Return On Invested Capital:
7.98%
Operating Margin:
13.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $601.3M | $723.5M | $723.3M | $191.2M | $191.8M | |
| Gross Profit | $319M | $371.6M | $343M | $98.7M | $95M | |
| Operating Income | $183.5M | $214.3M | $149.9M | $57M | $25.3M | |
| EBITDA | $219M | $270.6M | $211.8M | $71.5M | $41.1M | |
| Diluted EPS | $2.56 | $3.01 | $2.26 | $0.78 | $0.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $303.7M | $384.2M | $543M | $545.9M | $639.5M | |
| Total Assets | $651.7M | $726.7M | $1.5B | $1.5B | $1.7B | |
| Current Liabilities | $98M | $102.2M | $258M | $159M | $205.2M | |
| Total Liabilities | $221.5M | $221.5M | $949.5M | $817.5M | $889.5M | |
| Total Equity | $430.2M | $505.2M | $595.1M | $727.7M | $776.7M | |
| Total Debt | $106.1M | $100.1M | $668.8M | $625.6M | $648.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $174.9M | $208.2M | $152.3M | $60M | $52.6M | |
| Cash From Investing | -$546.3M | -$192.3M | -$45.4M | -$34.6M | -$19.6M | |
| Cash From Financing | $485M | -$94.2M | -$82.9M | -$22.8M | -$4.3M | |
| Free Cash Flow | $139.8M | $170.2M | $111M | $46.2M | $47.2M | |
AMPH
Sector
Market Cap
$1.2B
$28.4M
Price % of 52-Week High
59.82%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
6.54%
-1.32%
1-Year Price Total Return
-38.71%
-22.19%
Beta (5-Year)
0.913
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.29
200-day SMA
Buy
Level
$25.85
Bollinger Bands (100)
Buy
Level
23.18 - 28.84
Chaikin Money Flow
Buy
Level
678.7K
20-day SMA
Buy
Level
$26.44
Relative Strength Index (RSI14)
Buy
Level
55.77
ADX Line
Buy
Level
17.25
Williams %R
Neutral
Level
-23.5987
50-day SMA
Buy
Level
$25.61
MACD (12, 26)
Buy
Level
0.51
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
16.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8139)
Buy
CA Score
(Annual)
Level (0.02)
Buy
Beneish M-Score
(Annual)
Level (-2.4326)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.3506)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Stock Forecast FAQ
In the current month, AMPH has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AMPH average analyst price target in the past 3 months is $32.33.
-
Where Will Amphastar Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amphastar Pharmaceuticals, Inc. share price will rise to $32.33 per share over the next 12 months.
-
What Do Analysts Say About Amphastar Pharmaceuticals, Inc.?
Analysts are divided on their view about Amphastar Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amphastar Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Amphastar Pharmaceuticals, Inc.'s Price Target?
The price target for Amphastar Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $32.33 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AMPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amphastar Pharmaceuticals, Inc. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMPH?
You can purchase shares of Amphastar Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amphastar Pharmaceuticals, Inc. shares.
-
What Is The Amphastar Pharmaceuticals, Inc. Share Price Today?
Amphastar Pharmaceuticals, Inc. was last trading at $27.12 per share. This represents the most recent stock quote for Amphastar Pharmaceuticals, Inc.. Yesterday, Amphastar Pharmaceuticals, Inc. closed at $27.15 per share.
-
How To Buy Amphastar Pharmaceuticals, Inc. Stock Online?
In order to purchase Amphastar Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AMPH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AMPH
Sector
P/E ratio
12.04x
23.66x
PEG ratio
0.43x
-0.01x
P/B ratio
1.61x
1.84x
Price / LTM sales
1.85x
1.60x
Growth Metrics
AMPH
Sector
Revenue growth
0.33%
4.85%
Earnings growth
-53.32%
11.15%
Revenue (5-year growth)
17.82%
6.45%
Earnings forecast
$0.83
-$0.20
Profitability
AMPH
Sector
Profitability FY 2024
$361.4M
$3.6M
Return on invested capital
7.98%
-30.98%
Return on assets
6.91%
-27.62%
Return on equity
14.9%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
5
Balance Sheet
AMPH
Sector
Total cash
$278.6M
$27.2M
Short term investments
$70M
$25.7M
Total assets
$1.6B
$79.9M
Long term debt
$648.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
